Sector: MedicalGTx, Inc. (NASDAQ: GTXI)
Headlines
- GTx Announces Corporate Presentation at Lazard Capital Markets Annual Healthcare Conference
Nov 11, 2009 07:00 AM | GTXI
- GTx, Inc. Reports Third Quarter 2009 Corporate Results
Nov 09, 2009 07:04 AM | GTXI
- ProActive HavRx Stock Indexes: Highlights And Opportunities
Nov 07, 2009 06:18 PM | BNI, CRL, CVS, DNDN, FCX, GTXI
- GTx, Inc. Announces Third Quarter 2009 Corporate Results Conference Call and Webcast
Nov 04, 2009 08:01 AM | GTXI
- Closing: Late Charge Allows Stocks To End Volatile Trade On Upbeat Note
Nov 02, 2009 04:40 PM | CGNX, CIT, CUTR, DNR, EAC, F
- GTx Receives Complete Response Letter from FDA for Toremifene 80 mg New Drug Application
Nov 02, 2009 08:00 AM | GTXI
- GTx to Host Conference Call and Webcast to Provide Update on Status of Toremifene 80 mg New Drug Application
Oct 30, 2009 04:22 PM | GTXI
- This Fall Will Be Crazy For These Biotech Stocks
Oct 16, 2009 02:55 PM | ACOR, AMGN, CADX, GTXI, THRX, XNPT
- GTx Announces Phase III Clinical Development of Toremifene 20 mg on Course Following Planned Safety Review
Sep 14, 2009 06:00 AM | GTXI
- GTx Announces Corporate Presentation at Rodman & Renshaw Annual Global Investment Conference
Sep 02, 2009 07:00 AM | GTXI
- GTx Inc. (GTXI) Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
Sep 09, 2009 04:17 PM | GTXI, MRK, NDAQ
- GTx, Inc. Reports Second Quarter 2009 Corporate Results
Aug 10, 2009 06:53 AM | GTXI, MRK
- GTx, Inc. Announces Second Quarter 2009 Corporate Results Conference Call and Webcast
Jul 29, 2009 07:03 AM | GTXI
- GTx-758, an Oral LH Inhibitor for First Line Treatment of Advanced Prostate Cancer, Advances into Second Phase I Clinical Trial
Jul 07, 2009 07:06 AM | GTXI
- GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting
Jun 11, 2009 10:31 AM | GTXI
- GTx Announces Ostarine™ (MK-2866) Clinical Trial Data to be Presented at ENDO 2009
Jun 08, 2009 07:09 AM | GTXI
- GTx Announces Webcast of Corporate Presentation at Goldman Sachs 30th Annual Global Healthcare Conference
Jun 02, 2009 07:08 AM | GTXI
- GTx's Toremifene 80 Mg Increased Bone Mineral Density in Multiple Clinically Relevant Subpopulations of Prostate Cancer Patients on Androgen Deprivation Therapy
Jun 01, 2009 06:05 AM | GTXI
- GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Society of Clinical Oncology
May 28, 2009 07:01 AM | GTXI
- GTx, Inc. Reports First Quarter 2009 Results
May 11, 2009 06:53 AM | GTXI, MRK
- Form 4 GTX INC /DE/ For: Nov 10 Filed by: STEINER MITCHELL SHUSTER (10K)
Nov 12, 2009 04:59 PM
- Form 4 GTX INC /DE/ For: Oct 01 Filed by: HYDE JOSEPH R III (10K)
Oct 02, 2009 06:24 PM
- Form 4 SEAR TIMOTHY R G For: Oct 01 (10K)
Oct 02, 2009 06:21 PM
- Form 4 ROBINSON KENNETH S For: Oct 01 (10K)
Oct 02, 2009 06:20 PM
- Form 4 PONTIUS JOHN HOFMANN For: Oct 01 (10K)
Oct 02, 2009 06:18 PM
- Form 4 SEAR TIMOTHY R G For: Jul 01 (10K)
Jul 02, 2009 05:53 PM
- Form 4 GTX INC /DE/ For: Jul 01 Filed by: HYDE JOSEPH R III (10K)
Jul 02, 2009 05:43 PM
- Form 4 CARTER MICHAEL G For: Jul 01 (10K)
Jul 02, 2009 05:41 PM
- Form 4 PONTIUS JOHN HOFMANN For: May 07 (10K)
May 11, 2009 06:49 PM
- Form 4 KARR ROBERT W For: May 07 (10K)
May 11, 2009 06:40 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
GTXI
|
Compare to S&P
|
| YTD |
-78.32 %
|
-82.10 %
|
| 4 Weeks |
-64.43 %
|
-64.61 %
|
| 12 Weeks |
-62.02 %
|
-64.36 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -12.90 %
|
|
EPS Growth in Last Year: -6.06 %
|
|
Sales Growth in Last Quarter: -5.81 %
|
|
Sales Growth in Last Quarter: 18.07 %
|
|
